Literature DB >> 21958545

2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.

Martin J Walsh1, Kyle R Brimacombe, Henrike Veith, James M Bougie, Thomas Daniel, William Leister, Lewis C Cantley, William J Israelsen, Matthew G Vander Heiden, Min Shen, Douglas S Auld, Craig J Thomas, Matthew B Boxer.   

Abstract

Compared to normal differentiated cells, cancer cells have altered metabolic regulation to support biosynthesis and the expression of the M2 isozyme of pyruvate kinase (PKM2) plays an important role in this anabolic metabolism. While the M1 isoform is a highly active enzyme, the alternatively spliced M2 variant is considerably less active and expressed in tumors. While the exact mechanism by which decreased pyruvate kinase activity contributes to anabolic metabolism remains unclear, it is hypothesized that activation of PKM2 to levels seen with PKM1 may promote a metabolic program that is not conducive to cell proliferation. Here we report the third chemotype in a series of PKM2 activators based on the 2-oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamide scaffold. The synthesis, structure activity relationships, selectivity and notable physiochemical properties are described. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21958545      PMCID: PMC3224553          DOI: 10.1016/j.bmcl.2011.08.114

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  16 in total

Review 1.  Pyruvate kinase type M2 and its role in tumor growth and spreading.

Authors:  Sybille Mazurek; C Bruce Boschek; Ferdinand Hugo; Erich Eigenbrodt
Journal:  Semin Cancer Biol       Date:  2005-08       Impact factor: 15.707

2.  Pyruvate kinase M2 is a phosphotyrosine-binding protein.

Authors:  Heather R Christofk; Matthew G Vander Heiden; Ning Wu; John M Asara; Lewis C Cantley
Journal:  Nature       Date:  2008-03-13       Impact factor: 49.962

3.  Alternative splicing of the pyruvate kinase M gene in a minigene system.

Authors:  M Takenaka; K Yamada; T Lu; R Kang; T Tanaka; T Noguchi
Journal:  Eur J Biochem       Date:  1996-01-15

4.  Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis.

Authors:  Jill D Dombrauckas; Bernard D Santarsiero; Andrew D Mesecar
Journal:  Biochemistry       Date:  2005-07-12       Impact factor: 3.162

5.  The L- and R-type isozymes of rat pyruvate kinase are produced from a single gene by use of different promoters.

Authors:  T Noguchi; K Yamada; H Inoue; T Matsuda; T Tanaka
Journal:  J Biol Chem       Date:  1987-10-15       Impact factor: 5.157

6.  The human liver-type pyruvate kinase (PKL) gene is on chromosome 1 at band q21.

Authors:  H Satoh; K Tani; M C Yoshida; M Sasaki; S Miwa; H Fujii
Journal:  Cytogenet Cell Genet       Date:  1988

7.  Immunohistological demonstration of the same type of pyruvate kinase isoenzyme (M2-Pk) in tumors of chicken and rat.

Authors:  M Reinacher; E Eigenbrodt
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1981

Review 8.  Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells.

Authors:  Sybille Mazurek
Journal:  Int J Biochem Cell Biol       Date:  2010-02-13       Impact factor: 5.085

9.  The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth.

Authors:  Heather R Christofk; Matthew G Vander Heiden; Marian H Harris; Arvind Ramanathan; Robert E Gerszten; Ru Wei; Mark D Fleming; Stuart L Schreiber; Lewis C Cantley
Journal:  Nature       Date:  2008-03-13       Impact factor: 49.962

Review 10.  Understanding the Warburg effect: the metabolic requirements of cell proliferation.

Authors:  Matthew G Vander Heiden; Lewis C Cantley; Craig B Thompson
Journal:  Science       Date:  2009-05-22       Impact factor: 47.728

View more
  15 in total

Review 1.  Pyruvate kinase: Function, regulation and role in cancer.

Authors:  William J Israelsen; Matthew G Vander Heiden
Journal:  Semin Cell Dev Biol       Date:  2015-08-13       Impact factor: 7.727

2.  How chemoproteomics can enable drug discovery and development.

Authors:  Raymond E Moellering; Benjamin F Cravatt
Journal:  Chem Biol       Date:  2012-01-27

3.  M2 pyruvate kinase provides a mechanism for nutrient sensing and regulation of cell proliferation.

Authors:  Hugh P Morgan; Francis J O'Reilly; Martin A Wear; J Robert O'Neill; Linda A Fothergill-Gilmore; Ted Hupp; Malcolm D Walkinshaw
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-25       Impact factor: 11.205

Review 4.  Emerging Approaches for Targeting Metabolic Vulnerabilities in Malignant Glioma.

Authors:  Peter M Clark; Wilson X Mai; Timothy F Cloughesy; David A Nathanson
Journal:  Curr Neurol Neurosci Rep       Date:  2016-02       Impact factor: 5.081

Review 5.  Anticancer agents that counteract tumor glycolysis.

Authors:  Carlotta Granchi; Filippo Minutolo
Journal:  ChemMedChem       Date:  2012-06-08       Impact factor: 3.466

Review 6.  Regulation and function of pyruvate kinase M2 in cancer.

Authors:  Weiwei Yang; Zhimin Lu
Journal:  Cancer Lett       Date:  2013-06-18       Impact factor: 8.679

Review 7.  Global profiling strategies for mapping dysregulated metabolic pathways in cancer.

Authors:  Daniel I Benjamin; Benjamin F Cravatt; Daniel K Nomura
Journal:  Cell Metab       Date:  2012-10-11       Impact factor: 27.287

Review 8.  Stalling the engine of resistance: targeting cancer metabolism to overcome therapeutic resistance.

Authors:  Ethan B Butler; Yuhua Zhao; Cristina Muñoz-Pinedo; Jianrong Lu; Ming Tan
Journal:  Cancer Res       Date:  2013-04-22       Impact factor: 12.701

9.  Bioluminescence Methods for Assaying Kinases in Quantitative High-Throughput Screening (qHTS) Format Applied to Yes1 Tyrosine Kinase, Glucokinase, and PI5P4Kα Lipid Kinase.

Authors:  Mindy I Davis; Douglas S Auld; James Inglese
Journal:  Methods Mol Biol       Date:  2016

Review 10.  Dysregulated metabolism contributes to oncogenesis.

Authors:  Matthew D Hirschey; Ralph J DeBerardinis; Anna Mae E Diehl; Janice E Drew; Christian Frezza; Michelle F Green; Lee W Jones; Young H Ko; Anne Le; Michael A Lea; Jason W Locasale; Valter D Longo; Costas A Lyssiotis; Eoin McDonnell; Mahya Mehrmohamadi; Gregory Michelotti; Vinayak Muralidhar; Michael P Murphy; Peter L Pedersen; Brad Poore; Lizzia Raffaghello; Jeffrey C Rathmell; Sharanya Sivanand; Matthew G Vander Heiden; Kathryn E Wellen
Journal:  Semin Cancer Biol       Date:  2015-10-08       Impact factor: 15.707

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.